Abstract
Cardiovascular disease (CVD) remains the largest cause of mortality in most developed countries. Although recent failed clinical trials and Mendelian randomization studies have called into question the high-density lipoprotein (HDL) hypothesis, it remains well accepted that stimulating the process of reverse cholesterol transport (RCT) can prevent or even regress atherosclerosis. The prevailing model for RCT is that cholesterol from the artery wall must be delivered to the liver where it is secreted into bile before leaving the body through fecal excretion. However, many studies have demonstrated that RCT can proceed through a non-biliary pathway known as transintestinal cholesterol excretion (TICE). The goal of this review is to discuss the current state of knowledge of the TICE pathway, with emphasis on points of therapeutic intervention.
| Original language | English |
|---|---|
| Pages (from-to) | 440-451 |
| Number of pages | 12 |
| Journal | Trends in Pharmacological Sciences |
| Volume | 36 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jun 26 2015 |
Bibliographical note
Publisher Copyright:© 2015 Elsevier Ltd. All rights reserved.
Funding
This work was supported by grants provided by the National Institutes of Health: R00 HL096166 (J.M.B.), R01 HL122283 (J.M.B.), and R01 HL111932 (R.E.T). Illustrations were created by David Schumick and reprints are available with the permission of the Cleveland Clinic Center for Medical Art and Photography © 2015.
| Funders | Funder number |
|---|---|
| National Institutes of Health (NIH) | R01 HL122283, R00 HL096166 |
| National Heart, Lung, and Blood Institute (NHLBI) | R01HL111932 |
Keywords
- bile
- cholesterol
- lipoprotein
- reverse cholesterol transport
- transintestinal cholesterol excretion
ASJC Scopus subject areas
- Toxicology
- Pharmacology
